CUPiD: A cfDNA methylation-based tissue-of-origin classifier for Cancers of Unknown Primary
Dominic G. Rothwell(Engineering and Physical Sciences Research Council), Natalie Cook(Manchester Academic Health Science Centre)
Cited by 0
Related Papers
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
|Nature Medicine|2021|115
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma
|The Journal of Experimental Medicine|2012|95
A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary
|Nature Communications|2024|46
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
|Journal of Clinical Oncology|2025|11